98305-82-9

Basic information

• Product Name: 2-AMino-6-(4-(benzyloxy)phenyl)pyriMidin-4(3H)-one
• Synonyms: 2-AMino-6-(4-(benzyloxy)phenyl)pyriMidin-4(3H)-one
• CAS NO: 98305-82-9
• Molecular Formula: C₁₇H₁₅N₃O₂
• Molecular Weight: 293.3199
• Mol File: 98305-82-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-AMino-6-(4-(benzyloxy)phenyl)pyriMidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-6-(4-(benzyloxy)phenyl)pyriMidin-4(3H)-one(98305-82-9)
• EPA Substance Registry System: 2-AMino-6-(4-(benzyloxy)phenyl)pyriMidin-4(3H)-one(98305-82-9)

Safety Data

• Hazardous Substances Data: 98305-82-9(Hazardous Substances Data)

Upstream product

• 53090-45-2 ethyl 3-[4-(benzyloxy)phenyl]-3-oxopropanoate 
• 113-00-8 guanidine nitrate 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 100-39-0 benzyl bromide 

Downstream Products

• 98305-30-7 2-Amino-6-(4-benzyloxy-phenyl)-5-bromo-3H-pyrimidin-4-one 
• 98305-29-4 2-Amino-6-(4-benzyloxy-phenyl)-5-chloro-3H-pyrimidin-4-one 
• 98305-31-8 2-Amino-6-(4-benzyloxy-phenyl)-5-iodo-3H-pyrimidin-4-one 

Relevant articles and documents

HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase

The identification of novel, non-purine based inhibitors of xanthine oxidase is described. After a high-throughput screening campaign, an NMR based counterscreen was used to distinguish actives, which interact with XO in a reversible manner, from assay artefacts. This approach identified pyrimidone 1 as a reversible and competitive inhibitor with good lead-like properties. A hit to lead campaign gave compound 41, a nanomolar inhibitor of hXO with efficacy in the hyperuricemic rat model after oral dosing.

SUBSTITUTED AMINO-PYRIMIDONES AND USES THEREOF

This invention relates to novel compounds having the structural formula Ia or formula Ib below: (Ia,Ib), and their phatmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Abeta related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.